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Abstract
Background: Daptomycin is a cyclic lipopeptide with potent activity and broad spectrum against
Gram-positive bacteria currently used for the treatment of complicated skin and skin structure
infections and bacteremia, including right sided endocarditis. We evaluated the in vitro activity of
this compound and selected comparator agents tested against clinical strains of staphylococci and
enterococci collected in European medical centers in 2005.
Methods: A total of 4,640 strains from 23 medical centers located in 10 European countries,
Turkey and Israel (SENTRY Program platform) were tested for susceptibility by reference broth
microdilution methods according to Clinical and Laboratory Standards Institute guidelines and
interpretative criteria. Mueller-Hinton broth was supplemented to 50 mg/L Ca++ for testing
daptomycin. Results for oxacillin (methicillin)-resistant staphylococci and vancomycin-resistant
enterococci were analyzed separately.
Results: Oxacillin resistance rates among Staphylococcus aureus varied from 2.1% in Sweden to
42.5% in the United Kingdom (UK) and 54.7% in Ireland (29.1% overall), while vancomycin
resistance rates varied from 0.0% in France, Sweden and Switzerland to 66.7% in the UK and 71.4%
in Ireland among Enterococcus faecium (17.9% overall). All S. aureus strains were inhibited at
daptomycin MIC of 1 mg/L (MIC50/90, 0.25/0.5 mg/L; 100.0% susceptible) and only one coagulase-
negative staphylococci strain (0.1%) showed an elevated (>1 mg/L) daptomycin MIC value (4 mg/
L). Among E. faecalis (MIC50/90, 0.5/1 mg/L; 100% susceptible) the highest daptomycin MIC value was
2 mg/L; while among E. faecium (MIC50/90, 2/4 mg/L; 100% susceptible) the highest MIC result was
4 mg/L.
Conclusion: Daptomycin showed excellent in vitro activity against staphylococci and enterococci
collected in European medical centers in 2005 and resistance to oxacillin, vancomycin or
quinupristin/dalfopristin did not compromise its activity overall against these pathogens. Based on
these results and those of previous publications, daptomycin appears to be an excellent therapeutic
option for serious infections caused by oxacillin-resistant staphylococci and vancomycin-resistant
enterococci in Europe.
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Gram-positive bacteria, especially staphylococci and ente-
rococci, are extremely important pathogens causing infec-
tions in the hospital environment. Staphylococcus aureus,
coagulase-negative staphylococci (CoNS) and enterococci
are among the five most frequently isolated organisms
from nosocomial bloodstream infections (BSI) [1,2].
These three pathogens are responsible for approximately
one-half of the cases of BSI in North American medical
centers evaluated by the SENTRY Antimicrobial Surveil-
lance Program [1].
Oxacillin (methicillin)-resistant S. aureus (MRSA) is cur-
rently recognized as a major problem in hospitals world-
wide [3]. The 2004 National Nosocomial Infections
Surveillance (NNIS) system report identified methicillin
resistance in 59.5% of S. aureus infections in intensive care
unit (ICU) patients [4]. This represented an 11% increase
in resistance compared with rates for the period 1998 to
2002. The SCOPE project report showed a significant
increase in the proportion of S. aureus isolates resistant to
methicillin among patients in ICUs from 1995 to 2001
(22% vs. 57%; P < 0.001) [5]. In hospitalized pediatric
patients with staphylococcal BSI, the proportion express-
ing methicillin resistance increased from 10% in 1995 to
29% in 2001 [6]. Furthermore, MRSA has recently
emerged as an important cause of community-acquired
infection in many parts of the United States (USA) [7].
A dramatic rise in frequency of enterococcal infections
and the prevalence of vancomycin-resistant enterococci
(VRE) occurred during the 1990s in the USA, first in ICUs,
then essentially throughout hospitals [8-10]. The 2004
NNIS report indicated that nearly 30% of all enterococci
isolated from patients infected in ICUs were resistant to
vancomycin [4]. Although most European countries were
able to control the hospital dissemination of VRE in the
1990s, the prevalence of this pathogen has recently
increased dramatically in many European countries
[8,11].
Daptomycin is a cyclic lipopeptide derived from Strepto-
myces roseosporus [12-14]. The mode of action is unique in
that it binds to bacterial membranes, in the presence of
physiological levels of calcium ions [15,16]. Daptomycin
is primarily effective against Gram-positive bacteria, due
to its inability to penetrate the outer membrane of Gram-
negative organisms [17]. It is available as an intravenous
drug and exhibits linear kinetics and is rapidly bactericidal
[12,16-18]. Daptomycin is active against a wide range of
multidrug-resistant (MDR) organisms for which there are
very few therapeutic alternatives, such as MRSA and VRE.
Due to daptomycin's requirement of calcium to be
present for effective binding to the bacterial membrane,
susceptibility testing requires appropriate supplementa-
tion of calcium to simulate levels found in human serum
(45–55 mg/L) [14-16].
Daptomycin was approved by the USA Food and Drug
Administration (FDA) in September 2003 for the treat-
ment of complicated skin and skin structure infections
(cSSTI) at a dosage of 4 mg/kg every 24 hours; and more
recently for the treatment of S. aureus bacteremia with or
without right sided infectious endocarditis at a dosage of
6 mg/kg every 24 hours [12,17,19]. Daptomycin has also
been recently approved by the European Medicines
Agency (EMEA) for the treatment of cSSTI [20]. In addi-
tion, the European Committee for Antimicrobial Suscep-
tibility Testing (EUCAST) has assigned daptomycin
breakpoints for staphylococci and streptococci [21],
which are ≤ 1 mg/L for susceptible (similar to Clinical and
Laboratory Standards Institute [CLSI] and US-FDA break-
points) and ≥2 mg/L for resistance [22].
We have recently published a comprehensive analysis of
the antimicrobial susceptibility of Gram-positive bacteria
collected in European medical centers in previous years
(2002–2004) [11]. In the present study, we summarize
the antimicrobial activity results of daptomycin and sev-
eral comparator agents tested against 4,640 clinical sta-
phylococcal and enterococcal isolates collected in 2005.
Methods
Bacterial strains
A total of 4,640 contemporary clinical isolates, including
2,887 staphylococci (1,946 S. aureus and 941 CoNS) and
953 enterococci (646 Enterococcus faecalis and 307 E. fae-
cium), were evaluated in the present study. All isolates
were non-duplicate, consecutive, clinical strains collected
from patients hospitalized in 23 medical centers located
in 10 European countries, Turkey and Israel in 2005 (SEN-
TRY Program platform) following common protocols.
The isolates were collected according to site of infection.
Identifications were performed by the submitting labora-
tories and confirmed in the monitoring laboratory (JMI
Laboratories, North Liberty, Iowa, USA) using standard
biochemical algorithms and/or the Vitek System (bioMer-
ieux, Hazelwood, Missouri, USA).
Antimicrobial agents and susceptibility testing
Daptomycin and selected comparator agents were tested
by CLSI (formerly the NCCLS) criteria [22]. All strains
were tested for antimicrobial susceptibility by the broth
microdilution method. Dry-form, validated microdilu-
tion panels and broth reagents were manufactured by
TREK Diagnostics (Cleveland, OH, USA). Mueller-Hinton
Broth (MHB) adjusted to contain physiological levels of
calcium (50 mg/L) was used when testing daptomycin
[15]. Comparator agents included those representing thePage 2 of 9
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empiric or directed treatment of the indicated pathogen.
The isolates were categorized as susceptible and resistant
according to CLSI guidelines [22]. A daptomycin suscepti-
ble breakpoint of ≤ 1 mg/L was used for staphylococci,
while ≤ 4 mg/L was used for enterococci, as approved by
the USA-FDA, CLSI and EUCAST [12,20-22]. The follow-
ing quality control organisms were concurrently tested: E.
faecalis ATCC 29212, and S. aureus ATCC 29213.
Results
The isolates were collected mainly from bloodstream
infection (55.1%), skin and skin structure infections
(22.3%) and pneumonia (8.1%). France (940 strains;
20.3% of all isolates), Germany (848 strains; 18.3%) and
Italy (519 strains; 11.2%) contributed with the highest
number of strains; while Greece (78 strains; 1.7%), Israel
(187 strains; 4.0%) and Switzerland (217 strains; 4.7%)
supplied the lowest number of samples (Table 1). The fre-
quencies of oxacillin resistance among staphylococci and
vancomycin resistance among enterococci by country are
listed in Table 2, and showed that oxacillin resistance rates
varied from 2.1% in Sweden (187 strains) to 42.5% in the
United Kingdom (UK; 153 strains) and 54.7% in Ireland
(203 strains) among S. aureus (29.1% overall). Oxacillin
resistance rates were most elevated among CoNS strains,
varying from 53.3% in the UK (30 strains) to 83.3% in
Greece (24 strains). Vancomycin-resistant E. faecalis
strains were detected only in Italy (one strain; 1.6%) and
UK (five strains; 17.9%), while among E. faecium, the van-
comycin resistance rates varied from 0.0% in France, Swe-
den and Switzerland to 66.7% in the UK (18 strains) and
71.4% in Ireland (14 strains), with an all Europe rate of
17.9% (Table 2).
Daptomycin was generally very potent against the Gram-
positive organisms collected in European medical centers
in 2005 (Table 3). All S. aureus strains were inhibited at a
daptomycin MIC of ≤1 mg/L (100.0% susceptible) with a
MIC50 of 0.25 mg/L and a MIC90 of only 0.5 mg/L. A slight
trend toward higher daptomycin MIC values was observed
for MRSA (52.8% at 0.25 mg/L and 43.8% at 0.5 mg/L)
compared to oxacillin (methicillin)-susceptible S. aureus
(MSSA; 70.7% at 0.25 mg/L and 24.9% at 0.5 mg/L). This
very modest skewing was less apparent for CoNS where
the frequency of strains inhibited at 0.25 mg/L were 48.1
and 47.3%, and at 0.5 mg/L were 33.6 and 43.2% for oxa-
cillin (methicillin)-susceptible (MS-CoNS) and oxacillin
(methicillin)-resistant (MR-CoNS) strains, respectively.
Only one CoNS strain (0.1%) exhibited an elevated dap-
tomycin MIC value for an oxacillin-susceptible strain iso-
lated from a medical center located in Rome, Italy
(reproducible MIC value of 4 mg/L). All other CoNS
strains were inhibited at daptomycin MIC ≤1 mg/L (Table
3).
Daptomycin was also highly active against enterococci
(Table 3). Among 646 tested E. faecalis (MIC50, 0.5 mg/L;
MIC90, 1 mg/L; 100% susceptible) the highest daptomy-
cin MIC value was only 2 mg/L (2.2% of strains tested);
while among E. faecium (MIC50, 2 mg/L; MIC90, 4 mg/L;
100% susceptible) the highest MIC value was 4 mg/L.
MSSA strains showed high rates of susceptibility (>95%)
to most comparison antimicrobial agents tested except
erythromycin (85.9% susceptibility), ciprofloxacin
(93.0%) and levofloxacin (93.9%). In contrast, resistance
rates to many agents were high among MRSA strains
(Table 4). The most active compounds tested against this
pathogen (100.0% susceptible) were daptomycin (MIC90,
0.5 mg/L), linezolid (MIC90, 2 mg/L), teicoplanin (MIC90,
≤2 mg/L) and vancomycin (MIC90, 1 mg/L; Table 4).
CoNS showed higher rates of resistance compared to S.
aureus. The fluoroquinolones, ciprofloxacin and levo-
floxacin, were active against only 86.9 and 87.3% of MS-
CoNS, respectively. In contrast, daptomycin, linezolid
and vancomycin were the only compounds active against
100.0% of MR-CoNS at the susceptible breakpoint (Table
4). It is important to note the emergence of quinupristin/
dalfopristin resistance among both MRSA (98.6% suscep-
tible) and MR-CoNS (99.3% susceptible).
Daptomycin (MIC90, 0.5 mg/L; 100.0% susceptible),
ampicillin (MIC90, 2 mg/L; 99.4% susceptible) and line-
zolid (MIC90, 2 mg/L; 100.0% susceptible) were very
active against E. faecalis, and only six vancomycin-resist-
ant E. faecalis strains (0.9%) were detected in Europe in
2005 (Table 4). These strains were from Italy (one strains)
and the UK (five strains), and all six strains showed low
daptomycin MIC values (0.25 – 1 mg/L). On the other
hand, E. faecium exhibited high rates of resistance to most
antimicrobials tested. Resistance to vancomycin was
observed in 17.9% of E. faecium strains (Table 2) and only
daptomycin (MIC50, 2 mg/L and MIC90, 4 mg/L) and lin-
ezolid (MIC50, 1 mg/L and MIC90, 2 mg/L) were active
against all vancomycin-resistant E. faecium strains tested.
Furthermore, only 72.7% of vancomycin-resistant and
70.2% of vancomycin-susceptible E. faecium strains were
susceptible to quinupristin/dalfopristin (Table 4).
Discussion
The treatment of serious MRSA infections presents a great
challenge to clinicians, particularly bacteremias and infec-
tive endocarditis, for which bactericidal therapy is essen-
tial to maximize successful clinical outcomes [23,24].
Vancomycin has been the preferred antimicrobial agent to
treat such MRSA infections; however, the clinical efficacy
of this glycopeptide has become more limited [24-27]. InPage 3 of 9
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susceptibility (vancomycin-intermediate S. aureus [VISA])
or high-level vancomycin resistance (vancomycin-resist-
ant S. aureus [VRSA]), other reports have shown limited
bactericidal activity against a large proportion of strains
with vancomycin MIC values within the CLSI susceptible
range [22,27-30]. Linezolid and quinupristin-dalfopristin
represent alternative treatment options for serious MRSA
infections; however, these compounds also possess
important limitations. Quinupristin-dalfopristin, a strep-
togramin combination, requires a central venous access to
be administrated and has been linked to some adverse
events such as arthralgia and myalgia [31,32]. Concerns
with linezolid, an oxazolidinone, include possible hema-
tologic toxicity of long-term treatment and the fact that it
is a bacteriostatic agent against staphylococci and entero-
cocci and is not indicated for the treatment endocarditis
and serious infections in immuno-suppressed patients
[31,33].
Although they are relatively nonvirulent organisms, the
enterococci have become increasingly common nosoco-
mial pathogens because they are resistant to many antimi-
crobials and can survive in the environment for prolonged
periods of time. Enterococci are intrinsically resistant to
multiple antimicrobial agents. Furthermore, other agents
that are active in vitro, such as vancomycin, are not bacte-
ricidal at clinically achievable concentrations. As shown
in the present study, E. faecium is usually resistant to amp-
icillin, and this type of resistance has been reported as a
Table 2: Frequency of important resistance phenotypes by European nation.
Country MRSAa MR-CoNSa Vancomycin-resistant E. faecalis Vancomycin-resistant E. faecium
France 31.5 71.0 0.0 0.0
Germany 17.2 67.4 0.0 19.7
Greece 36.6 83.3 0.0 16.7
Ireland 54.7 66.7 0.0 71.4
Israel 46.0 80.0 0.0 40.0
Italy 38.3 82.4 1.6 19.4
Poland 27.2 81.3 0.0 4.3
Spain 25.3 61.9 0.0 14.3
Sweden 2.1 54.8 0.0 0.0
Switzerland 15.7 65.6 0.0 0.0
Turkey 30.9 74.4 0.0 8.6
UK 42.5 53.3 17.9 66.7
Overall 29.1 71.5 0.9 17.9
a. MRSA = oxacillin-resistant S. aureus and MR-CoNS = oxacillin-resistant CoNS.
Table 1: Number of strains tested from European nations in the 2005 surveillance sample.
No. tested by country:
Organism France Germany Greece Ireland Israel Italy Poland Spain Sweden Switzerland Turkey UK Total
S. aureus 594 471 41 203 113 240 213 241 187 102 188 153 2,746
Oxacillin-susceptible 407 390 26 92 61 148 155 180 183 86 130 88 1,946
Oxacillin-resistant 187 81 15 111 52 92 58 61 4 16 58 65 800
CoNS 224 187 24 3 30 182 16 42 31 90 82 30 941
Oxacillin-susceptible 65 61 4 1 6 32 3 16 14 31 21 14 268
Oxacillin-resistant 159 126 20 2 24 150 13 26 17 59 61 16 673
E. faecalis 104 117 7 38 34 61 40 39 96 21 61 28 646
Vancomycin-susceptible 104 117 7 38 34 60 40 39 96 21 61 23 640
Vancomycin-resistant 0 0 0 0 0 1 0 0 0 0 0 5 6
E. faecium 18 73 6 14 10 36 23 14 21 4 70 18 307
Vancomycin-susceptible 18 61 5 4 6 29 22 12 21 4 64 6 252
Vancomycin-resistant 0 12 1 10 4 7 1 2 0 0 6 12 55
Total 940 848 78 258 187 519 292 336 335 217 401 229 4,640Page 4 of 9
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tion therapy of a cell-wall active agent plus an aminogly-
coside has become the "standard of care" for patients with
serious enterococcal infections, such as endocarditis or
BSI, but the prevalence of high-level resistance to
aminoglycosides and to ampicillin are increasing, leaving
glycopeptides as the remaining class of active antimicrobi-
als. Clearly, the emergence of VRE has further complicated
therapeutic options [35].
Two antimicrobial agents have been approved specifically
for the treatment of VRE infections: quinupristin/dalfo-
pristin and linezolid [31,36]. However, quinupristin/dal-
fopristin MIC90 results (16 mg/L) for E. faecalis systemic
infections exceeds the maximum achievable serum con-
centrations, making this compound inactive for E. faecalis
[9,32], and resistance among E. faecium has been recently
increasing, especially in Europe among vancomycin-
resistant strains [11,35,37]. In this presented study, only
70% of E. faecium were susceptible to quinupristin/dalfo-
pristin. On the other hand, linezolid has potent in vitro
activity against both vancomycin-resistant E. faecalis and
E. faecium, as well as good therapeutic efficacy for VRE
bacteremia in mice [31,33,34]. However, as mentioned
previously, linezolid has not been recommended for the
treatment of endocarditis or serious infections in
immuno-suppressed patients due to its predominantly
bacteriostatic activity. In addition, the emergence of oxa-
zolidinone resistance has been reported, especially in
patients who receive prolonged courses of therapy
[33,38].
Conclusion
Daptomycin is the first member of a novel class of antimi-
crobial agents, the cyclic lipopeptides [13,14]. It has
broad-spectrum and potent bactericidal activity against
Gram-positive pathogens, including MRSA and VRE [39-
42]. This compound has demonstrated activity against
both growing and stationary-phase bacteria [12-14], [16-
18]. Here daptomycin was recognized as highly active
against S. aureus and CoNS, including oxacillin-resistant
strains. Only one strain showed a daptomycin MIC value
>1 mg/L (a CoNS strain with MIC value of 4 mg/L). Van-
comycin (MIC50, 1 mg/L) and linezolid (MIC50, 1 – 2 mg/
L) were active against all staphylococcal strains tested.
However, daptomycin (MIC50, 0.25 – 0.5 mg/L) was four-
fold more potent than these key comparison bacteriostatic
antimicrobials. Furthermore, all enterococci, including
vancomycin-resistant strains were susceptible to dapto-
mycin and resistance rates were relatively high to all other
compounds tested, except linezolid (see Table 4).
In summary, daptomycin showed excellent in vitro activ-
ity in a surveillance study against staphylococci and ente-
rococci collected in European medical centers in 2005.
Resistance to oxacillin, vancomycin, quinupristin/dalfo-
pristin did not compromise daptomycin potency against
these pathogens. Based on these results and those of pre-
vious publications [11,43,44], daptomycin appears to be
an excellent therapeutic option for serious infections
caused by MRSA, MR-CoNS and VRE (especially E. fae-
cium) in Europe.
Abbreviations
BSI – bloodstream infection
CLSI – Clinical and Laboratory Standards Institute
CoNS – coagulase-negative staphylococci
cSSTI – complicated skin and soft tissue infection
Table 3: Frequency of occurrence of daptomycin MIC values for key Gram-positive pathogens.
No. (%) of isolates inhibited at daptomycin MIC (mg/L) of:
Organism (no. tested) ≤0.06 0.12 0.25 0.5 1 2 4
S. aureus (2,746) 3 (0.1) 90 (3.3) 1.798 (65.5) 835 (30.4) 20 (0.7) - -
Oxacillin-susceptible (1,946) 2 (0.1) 75 (3.9) 1,376 (70.7) 485 (24.9) 8 (0.4) - -
Oxacillin-resistant (800) 1 (0.1) 15 (1.9) 422 (52.8) 350 (43.8) 12 (1.5) - -
Coagulase-negative staphylococci (941) 13 (1.4) 72 (7.7) 447 (47.5) 381 (40.5) 27 (2.9) - 1 (0.1)a
Oxacillin-susceptible (268) 6 (2.2) 30 (11.2) 129 (48.1) 90 (33.6) 12 (4.5) - 1 (0.4)a
Oxacillin-resistant (673) 7 (1.0) 42 (6.2) 318 (47.3) 291 (43.2) 15(2.2) - -
E. faecalis (646) 2 (0.3) 2 (0.3) 34 (5.3) 303 (46.9) 291 (45.0) 14 (2.2) -
Vancomycin-susceptible (640) 2 (0.3) 2 (0.3) 34 (5.3) 299 (46.7) 289 (45.2) 14 (2.2) -
Vancomycin-non-susceptible (6) - - - 4 (66.7) 2 (33.3) - -
E. faecium (307) - 1 (0.3) 3 (1.0) 19 (6.2) 72 (23.5) 151 (49.2) 61 (19.9)
Vancomycin-susceptible (252) - 1 (0.4) 3 (1.2) 18 (7.1) 60 (23.8) 120 (47.6) 50 (19.8)
Vancomycin-non-susceptible (55) - - - 1 (1.8) 12 (21.8) 31 (56.4) 11 (20.0)
a. Single strain of MS-CoNS.Page 5 of 9
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BMC Infectious Diseases 2007, 7:29 http://www.biomedcentral.com/1471-2334/7/29Table 4: Antimicrobial activity of daptomycin and selected comparators tested against European S. aureus and enterococcal isolates 
(2005).
MIC (μg/ml): % category
Organism (no. tested) 50% 90% Range Susceptible Resistant
S. aureus
Oxacillin-susceptible (1,946)
Daptomycin 0.25 0.5 ≤0.06–1 100.0 -a
Ciprofloxacin 0.25 0.5 ≤0.03–>4 93.0 6.2
Levofloxacin ≤0.5 ≤0.5 ≤0.5–>4 93.9 5.9
Erythromycin 0.25 >2 ≤0.06–>2 85.9 13.6
Clindamycin ≤0.25 ≤0.25 ≤0.5–>2 97.1 2.7
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5–>2 99.7 0.3
Quinupristin/dalfopristin ≤0.25 0.5 ≤0.25–>2 99.8 0.1
Chloramphenicol 8 8 4–>16 98.4 1.4
Rifampin ≤0.25 ≤0.25 ≤0.25–>2 99.4 0.5
Teicoplanin ≤2 ≤2 ≤2–8 100.0 0.0
Vancomycin 1 1 ≤0.12–2 100.0 0.0
Linezolid 1 2 0.25–2 100.0 -
Oxacillin-resistant (800)
Daptomycin 0.25 0.5 ≤0.06–1 100.0 -
Ciprofloxacin >4 >4 0.06–>4 6.9 93.0
Levofloxacin >4 >4 ≤0.5–>4 6.8 91.1
Erythromycin >2 >2 ≤0.25–>8 24.0 74.9
Clindamycin 0.5 >2 ≤0.25–>2 49.4 50.2
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5–>2 94.1 5.9
Quinupristin/dalfopristin 0.5 1 ≤0.25–>2 98.6 1.3
Chloramphenicol 8 16 ≤2–>16 89.7 5.6
Rifampin ≤0.25 >2 ≤0.25–>2 86.2 12.8
Teicoplanin ≤2 ≤2 ≤2–8 100.0 0.0
Vancomycin 1 1 0.25–2 100.0 0.0
Linezolid 1 2 0.12–2 100.0 -
Coagulase-negative staphylococci
Oxacillin-susceptible (268)
Daptomycin 0.25 0.5 ≤0.06–4 99.6 -
Ciprofloxacin 0.12 4 ≤0.03–>4 86.9 11.9
Levofloxacin ≤0.5 4 ≤0.5–>4 87.3 10.4
Erythromycin ≤0.25 >8 ≤0.25–>8 65.7 44.0
Clindamycin ≤0.25 ≤0.25 ≤0.25–>2 94.8 4.5
Trimethoprim/sulfamethoxazole ≤0.5 2 ≤0.5–>2 91.8 8.2
Quinupristin/dalfopristin ≤0.25 ≤0.25 ≤0.25–1 100.0 0.0
Chloramphenicol 4 8 ≤2–>16 97.4 2.6
Rifampin ≤0.25 ≤0.25 ≤0.25–>2 96.1 2.6
Teicoplanin ≤2 4 ≤2–16 99.6 0.0
Vancomycin 1 2 ≤0.12–4 100.0 0.0
Linezolid 1 1 0.12–2 100.0 -
Oxacillin-resistant (673)
Daptomycin 0.25 0.5 ≤0.06–1 100.0 -
Ciprofloxacin >4 >4 ≤0.03–>4 27.8 67.5
Levofloxacin 4 >4 ≤0.5–>4 28.1 62.9
Erythromycin >2 >2 ≤0.06–>2 27.2 72.7
Clindamycin <0.25 >2 ≤0.25–>2 67.0 32.5
Trimethoprim/sulfamethoxazole 2 >2 ≤0.5–>2 52.6 47.4
Quinupristin/dalfopristin ≤0.25 0.5 ≤0.25–>2 99.3 0.4
Chloramphenicol 4 >16 ≤2–>16 86.6 13.0
Rifampin ≤0.25 >2 ≤0.25–>2 85.3 13.4Page 6 of 9
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BMC Infectious Diseases 2007, 7:29 http://www.biomedcentral.com/1471-2334/7/29Teicoplanin ≤2 8 ≤2–>16 97.3 0.6
Vancomycin 1 2 ≤0.12–4 100.0 0.0
Linezolid 1 1 0.25–4 100.0 -
E. faecalis
Vancomycin-susceptible (640)
Daptomycin 0.5 1 ≤0.06–2 100.0 -
Ampicillin ≤1 2 ≤1–16 99.4 0.6
Ciprofloxacin 1 >4 0.12–>4 64.2 34.1
Levofloxacin 1 >4 ≤0.5–>4 66.1 33.0
Gentamicin (HL)b ≤500 >1000 ≤500–>1000 65.2 34.8
Streptomycin (HL)b ≤1000 >2000 ≤1000–>2000 62.0 38.0
Chloramphenicol 8 >16 ≤2–>16 68.9 30.4
Quinupristin/dalfopristin >2 >2 ≤0.25–>2 0.9 93.4
Teicoplanin ≤2 ≤2 ≤2 100.0 0.0
Linezolid 1 2 0.5–2 100.0 0.0
Vancomycin-resistant (6)
Daptomycin 0.5 - 0.25–1 100.0 -
Ampicillin ≤1 - 2 100.0 0.0
Ciprofloxacin >4 - >4 0.0 100.0
Levofloxacin >4 - >4 0.0 100.0
Gentamicin (HL)b >1000 - <500–>1000 16.7 83.3
Streptomycin (HL)b >2000 - ≤1000–>2000 16.7 83.3
Chloramphenicol 8 - - 100.0 0.0
Quinupristin/dalfopristin >2 - >2 0.0 100.0
Teicoplanin >16 - >16 0.0 100.0
Linezolid 1 - 1–2 100.0 0.0
E. faecium
Vancomycin-susceptible (252)
Daptomycin 2 4 0.12–4 100.0 -
Ampicillin >16 >16 ≤1–>16 13.1 86.9
Ciprofloxacin >4 >4 0.12–>4 7.5 78.2
Levofloxacin >4 >4 ≤0.5–>4 23.0 70.2
Gentamicin ≤500 >1000 ≤500–>1000 63.1 36.9
Streptomycin >2000 >2000 ≤1000–>2000 40.1 59.9
Chloramphenicol 8 16 4–>16 83.1 7.3
Quinupristin/dalfopristin 0.5 >2 ≤0.25–>2 70.2 17.9
Teicoplanin ≤2 ≤2 ≤2 100.0 0.0
Linezolid 1 2 0.25–2 100.0 -
Vancomycin-resistant (55)
Daptomycin 2 4 0.5–4 100.0 -
Ampicillin >16 >16 16–>16 0.0 100.0
Ciprofloxacin >4 >4 1–>4 3.6 92.7
Levofloxacin >4 >4 1–>4 7.3 92.7
Gentamicin (HL)b >1000 >1000 ≤500–>1000 47.3 52.7
Streptomycin (HL)b >2000 >2000 ≤1000–>2000 36.4 63.6
Chloramphenicol 8 16 ≤2–>16 87.1 6.5
Quinupristin/dalfopristin 1 >2 ≤0.25–>2 72.7 18.2
Teicoplanin 16 >16 ≤2–>16 41.8 41.8
Linezolid 1 2 0.5–2 100.0 0.0
a. - = No breakpoint has been established by CLSI [22]or US-FDA [12].
b. HL = High level resistance
Table 4: Antimicrobial activity of daptomycin and selected comparators tested against European S. aureus and enterococcal isolates 
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EUCAST – European Committee for Antimicrobial Sus-
ceptibility Testing
FDA – Federal Drug Administration
ICU – intensive care unit
MDR – multidrug-resistant
MHB – Mueller-Hinton broth
MIC – minimum inhibitory concentration
MR-CoNS – methicillin-resistant coagulase-negative sta-
phylococci
MRSA – methicillin-resistant Staphylococcus aureus
MS-CoNS – methicillin-resistant coagulase-negative sta-
phylococci
MSSA – methicillin-susceptible Staphylococcus aureus
NCCLS – National Committee for Clinical Laboratory
Standards
NNIS – National Nosocomial Infections Surveillance
UK – United Kingdom
USA – United States of America
VISA – vancomycin-intermediate Staphylococcus aureus
VRSA – vancomycin-resistant Staphylococcus aureus
VRE – vancomycin-resistant enterococci
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